Skip to main content
. 2020 Feb 18;21(4):1362. doi: 10.3390/ijms21041362

Figure 2.

Figure 2

Effect of icosapent ethyl compared with placebo on different endpoints in REDUCE-IT [80]. “From New England Journal of Medicine, Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., Doyle R.T. Jr., Juliano R.A., Jiao L., Granowitz C., Tardif J.C., Ballantyne C.M.; REDUCE-IT Investigators, Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, Volume No. 380, Page 11–22, Copyright © (2020) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.”